Mirum Pharmaceuticals, Inc.
NASDAQ:MIRMBiotechnology
Healthcare
$95.51 +3.81%
+$3.89 today
- Market cap
- $6.24B
- Beta
- 0.51
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$13.57
52W Low $47.89High $114.99
Volume 0.78M
Average 0.95M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$55.83M
FY 2025 · Annual
+440.7% YoYInvesting Cash Flow
-$23.95M
FY 2025 · Annual
Financing Cash Flow
$40.14M
FY 2025 · Annual
+126.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (83.99M) | (135.67M) | (163.42M) | (87.94M) | (23.36M) |
| Depreciation & Amortization | 975K | 3.24M | 10.83M | 23.63M | 24.24M |
| Deferred Income Tax | 595K | (6.58M) | 0 | 0 | 0 |
| Stock-Based Compensation | 23.09M | 27.01M | 35.02M | 48.44M | 71.42M |
| Change in Working Capital | 16.98M | (21.05M) | (22.64M) | 22.59M | (19.72M) |
| Accounts Receivables | 0 | (20.73M) | (43.97M) | (11.43M) | (48.06M) |
| Inventory | (495K) | (3.45M) | (4.39M) | (3.17M) | (8.45M) |
| Accounts Payables | 22.66M | 7.64M | 30.78M | 40.31M | 50.1M |
| Other Working Capital | (5.18M) | (4.51M) | (5.05M) | (3.13M) | (13.32M) |
| Other Non-Cash Items | (90.41M) | 12.91M | 69.26M | 3.6M | 3.24M |
| Operating Cash Flow | (132.76M) | (120.14M) | (70.94M) | 10.33M | 55.83M |
| Capital Expenditures | (19.02M) | (278K) | (20.11M) | (993K) | (954K) |
| Acquisitions (Net) | (19M) | (7.98M) | (212.76M) | 0 | 0 |
| Purchases of Investments | (198.03M) | (132.32M) | (27.33M) | (89.03M) | (97.43M) |
| Sales of Investments | 157.6M | 140.3M | 153M | 19.89M | 74.43M |
| Other Investing Activities | 127M | 7.98M | (20M) | (20M) | 0 |
| Investing Cash Flow | 48.55M | 7.7M | (107.2M) | (90.13M) | (23.95M) |
| Debt Repayment | 0 | 0 | 305.3M | 0 | 0 |
| Common Stock Issued | 6.91M | 107.37M | 216.68M | 17.7M | 40.14M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 66.55M | 1.72M | (185.39M) | 0 | 0 |
| Financing Cash Flow | 73.47M | 109.09M | 336.6M | 17.7M | 40.14M |
| Effect of Forex Changes | (1K) | 12K | (133K) | (1.3M) | 3.22M |
| Net Change in Cash | (10.75M) | (3.34M) | 158.32M | (63.4M) | 75.24M |
| Free Cash Flow | (151.78M) | (120.41M) | (91.05M) | 9.33M | 54.87M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$23.4M
+ D&A$24.2M
+ Stock-Based Comp$71.4M
+ Deferred Tax$0
- Working Capital-$19.7M
+ Other Non-Cash$3.2M
= Operating Cash Flow$55.8M
- Capex-$954.0K
= Free Cash Flow$54.9M
Analysis
FY2025 free cash flow is $54.9M. FCF conversion is -234.9% of net income. Operating cash flow was $55.8M, with capex of -$954.0K. The largest bridge item is Stock-Based Comp at $71.4M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 8-K | Current report | Nov 3, 2026 |
Does MIRM generate free cash flow?
Mirum Pharmaceuticals, Inc. (MIRM) generated $54.87M of free cash flow in fiscal 2025.
How much operating cash flow does MIRM produce?
Operating cash flow was $55.83M, before capital expenditures of $954,000.00.
Continue the stock analysis
Jump to another research area for this company.